A multi-site, open-label, Phase II, randomized, controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected, Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection

A Phase I-III, Multicenter Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Patients Selected According to Biomarker Status, With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (BZKF-Studie)

RNA Disruption Assay (RDA) Breast cancer Response EValuation for Individualized TherapY-02 (BREVITY-02)

A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC)

Master Screening Study to Determine Biomarker Status and Potential Trial Eligibility for Patients With Malignant Tumors (BZKF-Studie)

PARP-Inhibitor Reinduktion beim rezidivierenden Ovarialkarzinom: Versorgungsrealität in Bayern, translationale Biomarker und klinische Ergebnisse

Beobachtung der Medizinischen Rehabilitation auf die Lebensqualität von Patientinnen und Patienten mit chronisch myeloischer Leukämie (CML)

Nicht interventionelle Langzeitstudie (NIS) zum klinischen Einsatz von Biotest IVIGs in verschiedenen Indikationen. 

Hirnmetastasen im Brustkrebs-Netzwerk Deutschland